The lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas. The company has strategic collaborations with F. Hoffmann-La Roche Ltd, Biogen MA, Inc., and Merck entities.
Cyborg Score Rationale
Revenue grew 71.44% in 2024 to $35.58 million, but the company exhibits negative margins with an operating margin of -395.42%. Cash position enables funding into 2027, though Altman Z-Score of -2.91 indicates financial distress.
Top Insights
Phase 2 MOMENTUM Trial of Cemsidomide initiated in combination with dexamethasone for relapsed/refractory multiple myeloma
Q4 2024 revenue of $11.016 million surpassed expectations
Degronimids platform capable of hitting many more targets including previously undruggable ones while reducing drug resistance potential
5 analysts rate stock 'Strong Buy' with 12-month price target of $7.25, implying 296% upside
Named Competitors
Targeted Protein Degradation Platform — TPD therapeutics for oncology and immunology
IMiD-based Degrader — Small molecule targeted protein degradation
PROTAC Technology — Proteolysis targeting chimeras for cancer
Recent Developments
(February 2026) Cemsidomide Phase 2 MOMENTUM trial on track to initiate in Q1 2026
(September 2025) Cemsidomide Phase 1 data presented at International Myeloma Society meeting
(February 2025) Announced board appointments with oncology commercialization expertise
Open the full interactive C4 Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.